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Abstract
Our circulatory system is composed of numerous elements that are responsible for
transport of blood and delivery of essential nutrients and gases to vital downstream
tissues. Among these components that make up our circulation is vascular smooth
muscle (VSM), the primary muscular and contractile element of blood vessels and
regulator of many blood vessel functions. This is of particular importance as cardio‐
vascular disease (CVD), the number one killer of individuals in America and
worldwide, is primarily vascular in origin. Logically, identifying and characterizing
feasible targets that could control CVD are highly appealing and much desired. With
this in mind and given its centrality in control of vascular physiology, VSM has gained
wide attention as a plausible target to combat elements of CVD. This book chapter
focuses on VSM as a potential therapeutic target against CVD and will provide
overview of vascular anatomy and physiology and brief discussions about the pivotal
roles of VSM in CVD pathology, the influence of abnormal blood flow mechanics and
hemodynamics in CVD, neural control of VSM and the vasculature, and possible novel
cellular and molecular signaling targets that could be used to control and/or minimize
CVD. This chapter hopes to serve as a valuable resource for basic and applied scientists
as well as clinicians interested in understanding the crucial roles that VSM plays in
vessel physiology and pathology.
Keywords: Cardiovascular disease, cell signaling, cyclic nucleotides, hemodynam‐
ics, kinases, shear stress, vascular smooth muscle
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1. Introduction
Our circulatory system is comprised of a vast network of cellular elements and organs that
includes the heart, lungs, and vasculature composed of arteries, veins, and lymphatics. These
integrated factors serve essential roles in controlling flow of blood and lymph and in the
transport and delivery of essential nutrients, nutritive and vasoactive factors, and hormones
and gases. Vascular smooth muscle (VSM), the primary functional constituent of blood vessels,
serves critical regulatory roles of vessel relaxation and contraction to ensure adequate tissue
blood flow and to maintain proper localized arterial blood pressures and perfusion of
downstream tissues. These processes are elemental for normal vascular eutrophy and homeo‐
stasis and overall body health. Abnormalities in VSM anatomy and physiology, however, can
contribute to a myriad of primary and secondary vessel pathologies. Moreover, adult blood
vessels are normally contractile, quiescent, and static. However, under inimical conditions like
those associated with cardiovascular disease (CVD), VSM cells undergo phenotypic alterations
and revert to a growth-promoting, synthetic nature. In turn, this abnormal growth significantly
contributes to the emerging cardiovascular disorder. These complications alone present
significant health risks but also serve as confounding risk factors for associated cardiovascular
complications including hypertension, hypercholesterolemia, diabetes, and metabolic syn‐
drome. In fact, recent statements by the American Heart Association [1] and the World Health
Organization [2] point to dysfunctional VSM as a primary underpinning behind CVD.
Logically, therapeutically targeting VSM for clinical interventions aimed at controlling and
hopefully eradicating CVD is highly significant and essential.
The term “cardiovascular disease” defines a wide range of disorders, diseases, and conditions
that deleteriously affect the heart and blood vessels. If the heart is the primary organ affected
then this can include heart failure, various myopathies, arrhythmias and/or conduction delays,
valve complications, myocarditis and/or pericarditis. If the disorder is vascular in origin, then
problems could consist of occlusive plaque formation and atherosclerosis, arteriosclerosis,
coronary and/or peripheral artery disease (PAD), aneurysm formation, and/or restenosis and
remodeling. There are numerous forms and manifestations of CVD as well as broad prognoses
based on form and severity of the disorder. Abnormal biology of the vessel wall constitutes a
major element in the pathogenesis of most forms of CVD [1], and therefore the vessel wall and
particularly VSM makes a prime target for further discovery and potential therapeutic utility
against CVD.
The overall goal of this chapter is to present some of the more recent and novel theories
surrounding the primary vessel wall constituent, VSM, its importance in CVD, and its promise
as a therapeutic target. Discussion will include succinct overviews of normal vascular elements
and physiology with a focus on VSM, some common forms of CVD and their pathologies, the
role of VSM dysfunction in CVD etiology, the influence of flow alterations and hemodynamic
forces in vessel physiology and pathology, neural control of VSM and the vascular network,
unique molecular and cellular signaling pathways that may offer innovative and precise
targets for therapy in VSM, current therapeutic paradigms, and treatment strategies used to
combat VSM pathobiology ranging from homeopathic lifestyle modifications to pharmaco‐
Muscle Cell and Tissue4
therapies to interventional vascular approaches. This chapter concludes with an overview of
the therapeutic potential of VSM and its promise in the cardiovascular sciences. In all, this
chapter promises to offer a valuable resource for basic, applied, and clinical scientists by
providing a synopsis of the importance of VSM in normal vessel biology and vascular
pathology and its utility as therapeutic target to combat CVD.
2. Overview of vascular anatomy and physiology
Upon leaving the heart, blood enters the vasculature which is comprised of diverse tissues and
cell types. Conduit, large and small arteries, arterioles, capillaries, venules, veins, and lym‐
phatics are basic elements of this system, each with unique characteristics and functions. The
composition of the walls of each of these vessels also differs, based on size, location, and
function, and this dictates the presence or absence of the three major vessel wall layers. Starting
from the lumen that carries blood, the innermost blood vessel wall layer is the tunica (Latin for
tunic, membrane, coat) intima, and this is formed by squamous vascular endothelial cells
(VECs), a layer of connective tissue termed internal elastic lamina, and a basement membrane
containing laminin, heparan sulphate proteoglycans and collagen, and often the glycosami‐
noglycan hyaluronan. The tunica intima provides a key, selectively permeable interface
between flowing blood (which contains abundant growth factors and thrombogenic platelets)
in the lumen and the highly thrombogenic components of the subintimal vessel wall. This
important intimal layer is also largely responsible for controlling inflammation and medial
VSM proliferation and migration, and these intimal VECs operate by eliciting crucial signals
that, in communication with underlying VSM, help control blood vessel function. Hence, this
layer is of utmost importance in maintaining normal vascular homeostasis. Interestingly, the
endothelium of the tunica intima is continuous with the endocardium of the heart and is the
only layer present in all blood vessels of all sizes and anatomical locations.
The thick and muscular middle layer of blood vessels is called tunica media and this is composed
mainly of helical, spindle-shaped mononuclear VSM cells. The media also contains sparse
macrophages and fibroblasts along with an interstitial matrix consisting of collagens; glyco‐
proteins such as tenascin, vitronectin, and fibronectin; chondroitin sulphate proteoglycans
including versican; and elastic laminae. The tunica media provides structural support to blood
vessels and is the primary functional element that controls vascular constriction and dilation
(and hence, blood flow) based on metabolic needs of the downstream tissues. VSM within the
tunica media (in communication with intimal VECs) is predominantly responsible for mainte‐
nance of normal vascular physiology, yet dysfunction of medial VSM cells (and VECs) is a
major contributor to the pathogenesis of CVD (discussed later). The outermost layer of blood
vessels is termed tunica externa or adventitia, which is separated from the medial wall by the
external elastic lamina and is made up of sparse VSM and nerve cells, fibroblasts, fat cells, and
abundant connective tissue including elastin, collagen, and glycosaminoglycans that provide
structural support as the extracellular matrix (ECM). In larger caliber vessels, the adventitia
also contains unique small blood vessels termed vasa vasorum that feed nutrients to the thick
muscular vessel wall (when the vessel wall cannot get adequate oxygen and nutrition simply
Vascular Smooth Muscle as a Therapeutic Target in Disease Pathology
http://dx.doi.org/10.5772/60878
5
by diffusion from luminal blood). A schematic of blood vessel anatomy including these three







Figure 1. Blood vessel anatomy. The three primary circumferential layers of blood vessels include the innermost endo‐
thelium-rich tunica intima, the VSM-containing tunica media, and the outermost layer the tunica externa or adventitia.
Elastic laminae exist between these layers as well as within the medial wall. These layers serve critical functions in
maintaining normal blood flow and in providing key nutrients and gases to downstream tissues as well as in the re‐
moval of toxic by-products of metabolism. Dysfunction in their physiological abilities, however, can contribute to sig‐
nificant vessel disorders including uncontrolled growth which is foundational for the development of CVD.
Physiologically, blood vessels hold a critical place in our circulation between the heart,
downstream tissues, and the lungs. As such, a major function of blood vessels is to provide
blood flow complete with delivery of vital nutrients and gases (oxygen) to these essential
tissues and removal of used metabolic by-products and gases (carbon dioxide) targeted for
elimination via the lungs. Blood vessels also operate as highways for the distribution of
secreted hormones and other endocrine or paracrine factors as well as white blood cells
and/or platelets to their sites of action. Blood vessels also aid in the broader distribution of
water, solutes, and heat throughout the system. In VSM-specific fashion, blood vessels have
ability to regulate luminal caliber and hence, the amount of blood flow they carry, based on
local and immediate metabolic needs of downstream tissues. This is of obvious importance for
proper vascular function and tissue homeostasis and eutrophy. Blood vessels perform this
critical function through abilities to constrict (vasoconstriction) and relax (vasodilation)
through mechanisms fully dependent on functional medial VSM. Several other physiological
aspects of blood vessels involve their critical roles in growth adaptations during wound
healing or following surgical interventions or during vascular adaptations of exercise. These
normal blood vessel growth responses can involve angiogenesis (formation of new blood
vessels from existing vessels), vasculogenesis (de novo formation of new blood vessels),
arborization or branching of existing vessels, and/or collateralization to provide a new blood
supply to an existing vascular bed.
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3. Vascular smooth muscle
As mentioned, the primary structural, muscular, and functional unit of a blood vessel is the
medial wall comprised primarily of VSM. In adults, medial wall VSM cells are normally highly
differentiated and display a contractile phenotype (with abundant expression of contractile
proteins) which enables their abilities to contract and relax. By virtue of vasoconstriction and
vasodilation, VSM directly regulates lumen caliber and thus, arterial and venous tone and
vascular resistance. These, in turn, control distribution of blood flow in tissue-specific fashion
throughout the body. Mechanistically, VSM cells contain many thin actin filaments and
relatively few thick myosin filaments, which are arranged along the long axis of these cells. In
this arrangement, using the sliding filament theory and numerous states of actin and myosin
cross-bridge phosphorylation, VSM utilizes slow force development to produce prolonged
force maintenance with low energy utilization, thus helping in the maintenance of tetanic
vascular (myogenic) tone and blood flow control. Thus, vasoconstriction and vasodilation
represent major physiological functions of contractile VSM.
Under homeostatic unstimulated conditions, adult medial VSM cells are also predominantly
quiescent and lack significant growth, “resting” in the nonproliferative G0 phase of the cell
cycle. In this differentiated state, VSM cells have low turnover and minimal proliferative or
synthetic activities and are dedicated to their primary function of vasoconstriction/dilation.
These cells, however, show considerable plasticity and are able to phenotypically switch
between quiescent and synthetic phenotypes in response to local stimuli. So, following
activation from a variety of agonists, circulating factors, and/or hormones or cytokines or as a
result of injury or the onset of disease, these VSM cells dedifferentiate into noncontractile and
synthetic cells with reduced expression of contractile proteins and increased capacity to
proliferate, migrate, and produce ECM components. During this dedifferentiation process, the
cytoskeleton becomes highly organized with defined F-actin filaments, nuclear hypertrophy,
and enlarged Golgi. Along with these morphological changes these dedifferentiated cells
become highly sensitive to stimulation by mitogenic and chemotactic factors including
angiotensin II, platelet-derived growth factor, fibroblast growth factor, interleukins, and tumor
necrosis factor alpha. These processes and vasoactive signals allow VSM cells to contribute
significantly to the emerging vascular dysfunction through heightened proliferation, migra‐
tion, and synthetic properties foundational to CVD. This conversion to a growth-promoting
and synthetic embryonic phenotype represents a key event in the genesis and evolution of
numerous cardiovascular pathologies including atherosclerosis, restenosis following bypass
grafting or stent deployment, or aneurysmal disease as elements of CVD. Figure 2 shows a
schematic of the major functions of a VSM cell under healthy or pathologic conditions.
4. Cardiovascular disease
As discussed, abnormal VSM growth is elemental for development and maintenance of CVD,
which has historically ranked as the number one cause of morbidity and mortality in the United
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States and worldwide for many years [1,2]. Despite major advances in our knowledge of the
numerous contributing mechanisms for CVD and potential therapeutic strategies against
CVD, estimates suggest CVD-related deaths will continue to rise over the next 20 years or so
[1,2]. Certainly, notwithstanding these significant basic science and clinical advances, failure
in adequate clinical control of CVD highlights its complexity and points to the need for
continued study of the underlying mechanisms of and potential routes for control of CVD.
Of the many forms of CVD perhaps the most common is an occlusive disorder termed
atherosclerosis. Atherosclerosis is a gradual and progressive disease that involves combined
influences of heightened inflammatory status, locally dysfunctional metabolism, abnormal
vascular wall growth and remodeling, and the buildup of an occlusive plaque. As discussed,
the involvement of uncontrolled VSM growth is a basic foundation of the evolution phase of
atherosclerosis, and dedifferentiation of VSM cells into a growth-promoting and synthetic
phenotype contributes largely to the emerging and growing plaque. This process of enhanced
synthesis and proliferation of medial VSM cells can be slow and progressive and can occur
over many decades and may not elicit observable symptoms. This pathology often eventuates
in a stenotic plaque, either stable or complicated, which can then become jeopardized and lead
to lumen obstruction and diminution of blood flow with clear repercussions of reduced oxygen
and nutrient delivery to downstream tissues and diminished removal of toxic metabolites and
gases. The plaque can also rupture and send microthrombi into the downstream circulation
which can lodge in smaller blood vessels. If atherosclerosis occurs in the peripheral circulation,
then these processes could manifest as tissue necrosis with perhaps loss of the affected tissue
or limb. Of heightened significance, if this pathology occurs in the cerebral or myocardial
circulation, this could result in a cerebral or myocardial infarct (stroke or heart attack) with







Figure 2. Vascular smooth muscle cell function. VSM cells are normally quiescent and operate via vasoconstriction/
vasorelaxation to control local blood flows and pressures and downstream tissue perfusion. However, VSM dysfunc‐
tion leads to dedifferentiation to an embryonic phenotype, and under these pathologic conditions VSM loses its con‐
tractile characteristics and becomes synthetic, proliferative, and migratory, serving as basis for many forms of CVD.
Also shown in this schematic are cellular features of thick and thin filaments, dense plaques, and the cytoskeleton.
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5. Blood flow, vascular hemodynamics and neural control
The cardiovascular system is a closed circuit comprised of the heart and an elaborate network
of vessels in the systemic and pulmonary circulations. Biophysical forces and factors that
govern transportation of essential gases and metabolic fuels and nutrients as well as waste
products of metabolism are termed “hemodynamics” and are largely determined by local
tissue and cellular supply and demand balance. Hemodynamics, especially in the systemic
circulation, are regulated by intrinsic (ability of local tissues to regulate their blood supply)
and extrinsic (reliance on neural mechanisms to distribute blood flow at the tissue level) neural
control systems. These complex regulatory mechanisms rely on the ability of blood vessels to
properly respond to chemical cues in order to efficiently orchestrate where and how much
blood is being delivered and removed from various vascular beds. Dysfunctional intrinsic and
extrinsic neural control systems compromise efficient oxygen and nutrient delivery to tissues
and manifests in a variety of disease pathologies such as PAD, stroke, and/or heart attack.
As oxygenated blood leaves the left ventricle of the heart, it enters the aortic arch and exerts
biophysical forces on the arterial walls. Driving pressure, transmural pressure, and hydrostatic
pressure are all important forces that regulate blood flow and two major components of these
forces are tensile stress and shear stress. Tensile stress is the perpendicular force exerted by
flowing blood on the vessel wall and represents forces due to blood pressure [3]. In comparison,
fluid shear stress is the force parallel or tangential to the vessel wall which corresponds to the
frictional force of the blood in contact with the intimal endothelium [4]. These combined forces
are critical for stimulating both intrinsic and extrinsic neural control mechanisms in the
vasculature.
5.1. Autonomic nervous system and the vasculature
The autonomic nervous system is comprised of the complementary yet distinct sympathetic
(SNS) and parasympathetic (PSNS) nervous systems. Under normal physiological conditions,
these systems perform divergent regulatory functions on the vasculature. In general, the SNS
typically acts to constrict blood vessels, effectively reducing blood flow, while the PSNS
generally dilates blood vessels to increase flow. Autonomic dysfunction in the context of
abnormally high blood pressure is typically the result of an overly active SNS. This dysfunction
produces a constant neuronal discharge of sympathetic neurons resulting in tonic vasocon‐
striction of the VSM [5].
The SNS contains preganglionic sympathetic neurons in the ventral horn of the thoracolumbar
spinal cord which project their axons just outside of the sympathetic trunk and synapse with
postganglionic sympathetic neurons near its target organ. At the initial synapse, depolariza‐
tion of the presynaptic neuron triggers tethering, docking, and fusion of vesicles containing
the neurotransmitter Acetylcholine (Ach) to the axon hillock. Once Ach is released from the
presynaptic neuron, it binds to an ionotropic, nicotinic, cholinergic receptor on the postgan‐
glionic neuron, resulting in depolarization on the postsynaptic cell. In the context of carotid
artery blood flow, the postganglionic neuron projects onto, and synapses with, medial VSM
cells. At the postganglionic synapse, the neurotransmitter that is released is primarily norepi‐
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nephrine (NE). In similar fashion, vesicles containing NE are released at the postganglionic
synapse, yet they bind to metabotropic, adrenergic receptors on the VSM cells. VSM contains
both alpha 1 and beta 2 adrenergic receptors. NE will preferentially bind to the excitatory alpha
1 receptors causing vasoconstriction and reduced blood flow. Since it is well documented that
the carotid artery is tonically constricted, it is only after inhibition of this signal that the SNS
is able to be turned off by the PSNS, thereby resulting in carotid artery dilation and enhanced
cerebral blood flow. Essentially, the vasomotor area of the medulla is sending excitatory,
efferent output to the thoracolumbar section of the spinal cord which is innervating and
contracting carotid VSM. This action is executed until the vasomotor area receives an inhibitory
signal from the Nucleus Tractus Solitarii (NTS), at which point the SNS is inhibited while the
PSNS is activated.
In comparison to the constitutively active SNS, the PSNS is alternatively activated by the
carotid sinus when the carotid artery pressure increases. This means that as luminal pressure
exerts increased force on the vessel wall, the carotid sinus increases its firing frequency and
amplitude, activating the PSNS and effectively inhibiting SNS tonic discharge. The purpose of
its activation is to dilate the artery in an attempt to normalize or depress the increased pressure
that is currently acting on the vessel walls. The PSNS projects its preganglionic neurons directly
from the brainstem and/or sacral spinal cord towards, and in close proximity to, its target
organ(s). At this synapse, the preganglionic neuron releases Ach in a similar fashion as that
described for the SNS. The ensuing depolarization of the postganglionic neuron reaches the
carotid artery and releases Ach again, yet the mechanisms of action at this second synapse are
different than what occurs at the initial synapse. Here, Ach binds to beta 2, metabotropic,
muscarinic receptors located on the endothelium adjacent to the VSM cells in the medial layer.
After binding to the appropriate G-protein coupled receptor on the endothelium, a signaling
cascade is initiated that results in an influx of intracellular calcium and the synthesis of nitric
oxide (NO) from endothelial nitric oxide synthase (eNOS). NO can then stimulate broad and
multifaceted actions on downstream processes including those associated with cyclic nucleo‐
tide signaling (discussed below).
5.2. Intrinsic neural control mechanisms
Arterial tensile stress elicits myogenic tone and primarily modulates mechanoreceptor
feedback found in baroreceptors within conduit arteries (discussed below). Myogenic tone is
the inherent and tonic contractile response of VSM to increased luminal pressures and is a
critical component for determining vessel wall hypertrophy according to LaPlace’s equation:
T = r x P (T = tension; r = vessel radius; and P = pressure), whereby if vessel caliber or diameter
remains constant, any increase in intravascular pressure will elicit an increase in wall tension.
Since these two factors are proportional, the vessel wall thickens in order to help offset any
experienced increase in wall tension. In the high pressure environment of the systemic
vasculature failure to adapt can result in increased matrix metalloproteinase (MMP) activity,
causing vessel wall thinning and ensuing aneurysmal formation [6]. The other key force in
regulating blood flow is fluid shear stress. This tangential force is exerted on intimal endothe‐
lium and elicits VSM relaxation through canonical dilatory (largely NO-mediated) pathways.
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The mechanical stimulation of intimal VECs by luminal blood flow activates nonselective
cation channels (TRP channels) within the cellular plasma membrane [7]. The resulting
increase in intracellular calcium facilitates activation of eNOS and yields NO as a by-product
of L-arginine to L-citrulline conversion [8]. As a diatomic gas, NO freely diffuses across the
VEC membrane and travels in paracrine fashion to abluminal VSM cells. Here, NO binds to
the heme moiety on soluble guanylate cyclase (sGC) and dephosphorylates guanosine
triphophosphate (GTP) to elicit pyrophosphate (PPi) and cyclic GMP. Two cyclic GMP
molecules can then bind to the regulatory subunit of the serine/threonine (Ser/Thr) protein
kinase G (PKG), which in turn phosphorylates a vast number of intracellular proteins to
include ion channels, phospholamban, myosin light chain phosphatase, and other phosphor‐
ylatable targets including vasodilator-stimulated serum phosphoprotein (VASP), a topic of
interest discussed later in this chapter. Ultimately, PKG activation results in the resequestration
of calcium within the sarcoplasmic reticulum and induces VSM relaxation resulting in vessel
dilation and increased blood flow.
5.3. Extrinsic neural control mechanisms
Of all our organs that receive systemic blood flow, the cerebral circulation is of critical
importance. According to the American Heart Association, stroke is a leading cause of death
and the leading cause of adult disability in the United States [1]. Ischemic stroke, hemorrhagic
stroke, and transient ischemic attacks all result from failure of oxygenated blood to reach the
brain. In order to maintain appropriate cerebral blood pressure and constant brain perfusion,
numerous cardiovascular and neural control mechanisms exist that act cooperatively to ensure
adequate and appropriate cerebral circulation. The carotid sinus baroreceptor reflex is partly
responsible for maintaining and regulating blood flow to the brain through local and systemic
regulation of blood pressures. The carotid sinus innervates the internal carotid artery just distal
to the bifurcation of the common carotid artery. Here, the sensory fibers of the carotid sinus
extend into the medial VSM layer of the internal carotid artery. These sensory nerve endings
sense stretch (via geometric alteration of resident TRP channels) within the blood vessel and
follow the baroreceptor reflex arc. The source of this stretch is typically caused by an increase
in intraluminal pressure, which forces the vessel to expand in diameter in order to contain an
elevated blood volume within a defined enclosed space (the vessel walls). These volume and
pressure changes are also reflected as increased transmural pressure that is exerted by the
freely flowing blood on the vessel wall and incidentally on the nerve terminals of the carotid
sinus. Following stimulation, an excitatory signal is generated by an influx of cations entering
the nerve terminal and the generation of a depolarization event. This afferent signal travels up
the sinus nerve and connects to the glossopharyngeal nerve, which proceeds and terminates
at the NTS in the brainstem. Once the signal has reached the brainstem, a series of excitatory
or inhibitory interneurons communicate and are either stimulated or inhibited, which will
differentially activate or inhibit one of the two divisions of the autonomic nervous system
previously described. However, under abnormal conditions in the cerebral vasculature or
carotid arteries, these control mechanisms may become compromised, thereby resulting in
dysfunctional baroreceptor reflex mechanisms and compromised cerebral blood flow [5,9]. On
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a broader scale, any obstruction or dysfunction at any point along this reflex arc may be
instrumental in the pathogenesis of stroke and/or CVD as a whole [10].
5.4. Physiological blood flow profiles
Four types of physiological blood flow dominate the circulation: 1) pulsatile, 2) oscillatory, 3)
laminar, and 4) turbulent [4,11]. Pulsatile and oscillatory blood flows are similar and result
from periodic fluctuations in the upstream pumping of the heart in relation to downstream
“vacuum” or pulling forces generated by the respiratory and skeletal muscles as well as
changing metabolic demands. Since balance between laminar and turbulent flow is important
for moderation of flow-mediated stresses and the development of CVD, ensuing discussion
focuses on these two forms of blood flow. Continuous (unidirectional) laminar blood flow
represents uninterrupted flow that occurs at or near the capillary level and is frequently
studied in cell culture perfusion systems or computer modeling simulations. Laminar flow is
characterized by layered blood flow in the absence of detectable blood velocity fluctuations or
turbulence (e.g., eddies, whorls, and flow reversals). By convention, blood flow is laminar
when Reynold’s number (Re), a ratio of inertial to viscous forces of a solution, is below 2000,
where Re=2rvp/n with r = radius, v = velocity, p = density, and n = viscosity. Re exceeds 3000
under conditions of turbulent flow. When Re is high, it means that the inertial forces outweigh
the viscous forces of the liquid. Because stenotic vessels create a pressure drop distal to the site
of occlusion, blood velocity increases at these sites and creates audible turbulence with
extremely high Re values. Turbulent blood flow, then, is associated with changes in the layered
context of flow as seen in laminar settings and is correlated with increased stresses on the vessel
wall. Turbulent blood flow is also caused by branching or arborization of blood vessels (at
bifurcations of arteries, for example) or by lesions or plaque located along the luminal wall
which creates flow obstructions. Any local vascular region with a calculated Re > 3000 is
associated with elevated risk for developing vascular occlusions (plaque) at that site.
Considering the importance of laminar flow in maintaining proper vascular homeostasis and
turbulent or erratic blood flow in contributing to vascular dysfunction underlying CVD, we
began studies aimed at investigating the influence of altered blood flow and flow-mediated
shear stress on VSM migration. Using a newly developed in vitro flow apparatus with
controlled fluid viscosity (ViscoLab4000) and a newly developed in vitro wound healing and
migration assay (Ibidi microchannel VI.4), preexposure of rat VSM cells to 4 hours of elevated
shear stress (10 dyn/cm2) significantly reduced serum-stimulated migration compared to static
controls (SC) with no observable changes in cell morphology through 16 hours (Figure 3).
These early findings support our notion that elevated fluid shear stress protects against
enhanced VSM cell migration as occurs in the setting of CVD.
These results demonstrate the importance of homeostatic levels of fluid shear in maintaining
normal vessel function and are commensurate with other studies that have shown this time
point and level of fluid shear stress to be physiologically relevant in reducing migration using
non-in-situ migration assays [12,13]. It is important to accept the findings of these previous
studies with some prudence since removing cells from their perfusion location and seeding
them elsewhere can disrupt focal adhesions and other cytoskeletal arrangements formed in
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response to fluid flow and that are necessary for proper cellular and cytoskeletal dynamics.
Due to this shortcoming, we developed this novel wound-healing assay that utilizes an
ultraviolet laser and LCM microscopy (Zeiss Palm Laser LCM) to precisely control and
effectively denude adherent VSM cells from the perfusion channel substrate following
exposure to fluid shear stress in a more physiological setting (without the aforementioned
adverse confounding effects found in many traditional migration assays). This new technique
allows the researcher to perfuse and injure cells in the same location without the deleterious
effects of trypsinization and disruption of normal cellular architecture (including, notably,
focal adhesions and cytoskeletal components). Channels are promptly washed with complete
media prior to imaging at time zero. Migration time points are carried out up to 16 hours in
order to prevent proliferation effects on wound closure rates. To further increase the accuracy
and throughput of our migration measurements, we will use the motorized stage of the
confocal microscope that is equipped with X, Y, Z coordinate control and on-stage incubator
to perform simultaneous time-lapse analysis on multiple wounds.
As mentioned, one of the main functions of a healthy endothelial layer is to provide a key
interface between blood flowing in the lumen and the underlying subintimal layer. When this
functional endothelium becomes jeopardized, increased fluid shear stress experienced by the
underlying medial VSM cells negatively contributes to arterial dysfunction. It has been shown
that increased continuous laminar flow can improve re-endothelialization and attenuate VSM
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Figure 3. Fluid shear stress reduces migration of VSM cells. Using a newly developed laser capture microdissection
(LCM)-assisted wounding assay to estimate cell migration, rat primary VSM cells exposed to increased shear stress
show significantly reduced ability to migrate in response to serum compared to static control (SC) cells. Photomicro‐
graphs show confluent VSM cells exposed to a wounding scrape injury and treated with static flow (SC) or elevated
flow (shear stress 10 dyn/cm2) for 4 hours with continual exposure through 16 hours. A and B are photos taken after 4
hours pretreatment of 0 (SC) or 10 dyn/cm2, and C and D represent photos taken after continual exposure for 16 hours.
Arrows shown in B and D represent direction of flow. E shows measurements of percent recovery of the wound width
normalized to time 0 for SC and flow-exposed cells.
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by exposed VSM and the presence of physical obstructions such as intimal plaque promotes
VSM cell proliferation and migration as underpinnings of deleterious vessel growth and
remodeling [14,15]. This pathogenic feed-forward mechanism has poor implications for proper
vessel function and tissue perfusion.
6. Vascular endothelium
In addition to the essential VSM and autonomic neural mechanisms, a functional endothelium
is equally important for appropriate blood flow control and modulation. VEC dysfunction is
increasingly accepted as a common trait of nearly all forms of CVD and is often the initial insult
in CVD pathogenesis. Though environmental and genetic factors consistently contribute to
these disease states as well, the onset of vascular endothelial dysfunction can also be caused
by smoking, hypertension, and/or diabetes [1]. Contrary to this evidence, Horvath and
colleagues argue that arterial stiffness is not directly related to a properly functioning endo‐
thelium [9]. This is true in the sense that the mechanical elasticity of the vessel may compress
or expand due to pressure changes alone, but a functional endothelium is nonetheless
important for its contribution to baroreceptor function and is often a target for CVD prevention.
It is well described that reduced NO bioavailability within the vasculature has a direct
influence on VEC dysfunction [5]. Nonetheless, in the absence of an intact or functional
endothelium, the VSM layer is still capable of receiving NO from alternate NOS isoforms
independent of the endothelial layer. For example, inducible nitric oxide synthase (iNOS)
either from circulating cells or platelets or from local adventitial nerves can provide VSM with
bioavailable NO independent of endothelial contribution. Also, since iNOS is located within
VSM it can intrinsically synthesize NO, in turn facilitating vasorelaxation in autocrine fashion.
It should be noted though that the canonical pathway of vasodilation begins with VEC
activation as described.
In sum, hemodynamics and intrinsic and extrinsic neural control of blood flow including
sensory input to the carotid sinus and the ensuing baroreflex pathway are essential, yet can
become compromised under many disease states. The causes of this dysfunction are not
entirely understood, but research suggests that there is a direct link between autonomic output
and neural integrity and vascular function/dysfunction and the establishment and/or mainte‐
nance of CVD. Thus, the preservation of the baroreceptor reflex within the carotid sinus as
well as intrinsic/extrinsic neural control mechanisms are essential for ensuring adequate
arterial blood supply to the brain in CVD prophylaxis.
7. Treatment strategies
Several treatment strategies currently exist to control and/or minimize symptoms associated
with CVD. First, often the most prudent forms of CVD therapy involve lifestyle modifications,
and many of these are based on known risk factors for CVD. Specific lifestyle choices may
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already be in place in certain individuals in preventive/prophylactic measures and some of
them may not be relevant to every CVD patient. Nonetheless, several examples of lifestyle
modifications in either preventive fashion or following CVD diagnosis include appropriate
weight control (keeping within the recommended BMI limits), particularly for increased waist-
level fat or central fat (i.e., midline adiposity), appropriate control of diabetes and hypertension
(if previously diagnosed), smoking cessation, low to moderate consumption of alcohol, an
active lifestyle complete with regular moderate aerobic exercise, adequate and fitful sleep, and
proper and well-balanced diet and nutrition [16]. In conjunction with these healthy lifestyle
choices, the next line of defense against CVD often involves pharmacotherapy, also either
already in place via prophylaxis (such as one-a-day baby aspirin, multivitamins including
folate and B-complex) or prescribed against a form of CVD. Common pharmacotherapeutic
strategies include antihypertension medication (beta-blockers, angiotensin-converting
enzyme inhibitors or angiotensin receptor blockers, diuretics), anticholesterol medications
(statins), calcium signaling blockers, and agents to maintain proper insulin/glucose balance
for diabetic patients. Antiplatelet therapies are also commonly prescribed for CVD patients.
Following or concomitant with appropriate drug therapies can be surgical interventions to
alleviate the problem. This can be of a variety of interventions including coronary artery or
peripheral artery bypass grafting, transluminal angioplasty, and/or stent placement and
deployment, depending on the nature of the complication. With many of these interventions,
unfortunately, iatrogenesis or adverse side effects often occur, and the ensuing results can be
even more significant than the original disorder.
8. Molecular and cellular signaling
Mechanistically, a wide variety of molecular and cellular signaling pathways and signal
transduction processes have been theorized as serving key regulatory roles in the dedifferen‐
tiation and phenotypic conversion of VSM cells and subsequent vessel wall remodeling that
leads to CVD. Among these, cyclic nucleotides and their predominantly kinase-driven
downstream pathways represent significant regulatory factors in determining vascular
physiology and pathology. Cyclic nucleotide signaling consists of purine and pyrimidine cyclic
monophosphates, many of which have characteristics that allow them to serve as biologically
important second messengers. The family of purine cyclic nucleotides consist of the well-
known adenosine 3´,5´-cyclic monophosphate (cyclic AMP) and guanosine 3´,5´-cyclic
monophosphate (cyclic GMP) and the lesser known inosine 3´,5´-cyclic monophosphate (cyclic
IMP) and xanthosine 3´,5´-cyclic monophosphate (cyclic XMP). These signals operate primarily
through protein kinase-driven phosphorylation events on downstream targets to exert
functional control over a wide variety of cellular processes in a myriad of mammalian tissues.
In the cardiovascular system, cyclic AMP and cyclic GMP are ubiquitous and are established
as critical second messengers with abilities to regulate crucial homeostatic and pathophysio‐
logical functions. There also exists the less characterized family of cyclic pyrimidine nucleoti‐
des cytidine 3´,5´-cyclic monophosphate (cyclic CMP), uridine 3´,5´-cyclic monophosphate
(cyclic UMP), and thymidine 3´,5´-cyclic monophosphate (cyclic TMP); however, their
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physiological/pathophysiological importance in VSM and/or during CVD is not well under‐
stood.
As mentioned, several molecules exist in this wide family of cyclic nucleotides that are
considered to be true second messengers. A second messenger is defined as being generated
by a first-messenger-regulated enzyme, being activated by targeted effector proteins, exerting
defined biological effects, being degraded by specific inactivation mechanisms, and whose
effects can be duplicated by membrane-permeable analogues and/or bacterial nucleotidyl
cyclase toxins. [17] Accordingly, both cyclic AMP and cyclic GMP are considered the tradi‐
tional second messengers, being generated by membrane-bound and/or soluble cyclase
enzymes, exerting many effects via intracellular kinases and/or nonkinase targets such as ion
channels, have broad biological effects, are inactivated by a family of phosphodiesterases
(PDEs), and whose effects can be mimicked by specific analogues or toxins. Also, new theories
suggest that the pyrimidines cyclic CMP and cyclic UMP are in fact emerging second messen‐
gers in that they also fulfill these criteria [17,18].
The most recognized cyclic nucleotide second messengers are cyclic AMP and cyclic GMP
which are synthesized and operate in similar mechanistic fashion. Cyclic AMP is generated
through several different avenues including adenylate cyclase (AC) stimulation by direct
agonists or following beta-stimulation or through G protein-coupled receptor activation.
Following stimulation of AC, adenosine triphosphate (ATP) is dephosphorylated to produce
cyclic AMP and PPi. Similarly, following activation of GC through natriuretic peptides
(activating particulate GC) or from the gaseous ligands (NO) or carbon monoxide (CO) which
activate soluble GC, GTP is dephosphorylated to yield cyclic GMP and PPi. Cyclic AMP and
cyclic GMP operate largely through downstream phosphorylation events on Ser/Thr or
tyrosine (Tyr) residues on target proteins and serve diverse roles in normal vascular physiol‐
ogy and homeostasis and during the pathogenesis of CVD. The preferred target proteins for
cyclic AMP and cyclic GMP are protein kinase A (PKA) and PKG, respectively [19]. Much of
the work from our lab over the past few years has focused on cyclic AMP and cyclic GMP and
their abilities to target downstream phosphorylatable substrates mainly through PKA and
PKG to elicit functional control over a variety of physiological and pathophysiological
parameters elemental to CVD. Some of our latest studies have identified the Ser/Thr kinases
PKA, PKG, protein kinase C (PKC), and the metabolic gauge AMP-activated protein kinase
(AMPK) as biologically important regulators of VSM proliferation, migration, and chemotaxis;
ECM and MMP balance; and cellular apoptosis or necrosis using a variety of experimental
approaches and commercially available rodent VSM cells, primary rodent VSM cells, and
human primary VSM cells. We have observed capacity of Ser/Thr-specific protein phospha‐
tases (PPs) in moderating these kinase activities and in maintaining proper phosphorylative
balance. We have also witnessed abilities of the Ser/Thr PPs to elicit control over VSM growth
independent of direct kinase involvement. Additionally, many of these studies performed in
cultured cells have been validated in whole animal models of injury-induced VSM growth,
and these findings have verified biological ability of these cyclic nucleotide systems to operate
in a whole body setting. Lastly, we have solidified these observations obtained in rodent
models by recapitulating them in human primary coronary artery VSM preparations, thus
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adding translational relevance to these basic science findings. Certainly, the capacity of cyclic
AMP and cyclic GMP and their phosphorylatable kinase and PPi targets to control deleterious
growth of VSM is significant and of particular importance for VSM-specific CVD. These
observations provide important new perspectives on vessel wall biology and cell signaling
and also highlight potential new targets that could be used to combat CAD and PAD and
associated vascular occlusive disorders. Figure 4 depicts chemical structures of cyclic AMP
and cyclic GMP, respectively.
Cyclic AMP                                                   Cyclic GMP 
Figure 4. Chemical structures of cyclic AMP and cyclic GMP, respectively.
9. Vasodilator-stimulated phosphoprotein
Following generation of cyclic AMP and cyclic GMP and activation of their respective kinases
PKA and PKG (among others, as discussed below), these kinases then target a variety of
proteins and other factors to elicit functional consequences. Among these numerous bioactive
targets is vasodilator-stimulated phosphoprotein or VASP. VASP belongs to the Ena/VASP
Homology (EVH) family of cytoskeletal proteins that play essential roles in cellular dynamics
and function. These proteins are involved in intracellular signaling processes and regulate
“outside-in” communication via integrin–ECM interactions. VASP is comprised of an N-
terminal EVH1 domain (targets focal adhesion and membrane domains), a proline-rich mid-
region that binds to Src-homology 3 (SH3) domains, and WW domain-containing proteins that
aid in Ser/Thr binding, and a C-terminal EVH2 domain that mediates tetramerization and
actin/focal adhesion binding. Figure 5 shows a schematic of the primary VASP sequence
including essential EVH1 and EVH2 domains.
1 380 a.a. 5 Catalytic domain 225 377 
EVH 1 N C EVH 2 
113 
Figure 5. Schematic for the primary sequence of VASP complete with an N-terminal EVH1 domain (that targets focal
adhesion/membrane domains) and a C-terminal EVH2 domain that targets focal adhesion/actin binding. (Adapted
from [20])
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VASP as a Ser/Thr-containing protein was originally characterized as a substrate for cyclic
nucleotide-directed kinase-mediated phosphorylation signals, with cyclic AMP-driven PKA
preferentially phosphorylating VASPSer157 and cyclic GMP-directed PKG primarily acting on
VASPSer239 [21-24]. To date, at least four distinct Ser/Thr phosphorylation sites have been
identified on VASP: Ser157 and Ser239 as well as Thr278 and Ser322 [25-27]. Interestingly, despite
this original characterization of cyclic nucleotide-directed kinases “selectively” phosphory‐
lating discrete Ser/Thr residues on downstream substrates including VASP, emerging reports
from our lab and others have documented crosstalk and promiscuity of these and other
Ser/Thr kinases to phosphorylate discrete residues on VASP. Recent observations from our
laboratory in commercial [28] and primary VSM cells [19,29-31] as well unpublished findings
in human primary coronary VSM cells document capacities of cyclic AMP and cyclic GMP to
not only phosphorylate their respective canonical targets PKA and PKG but to also have
abilities to phosphorylate other kinases as well. In these studies, findings reveal that cyclic
AMP, stimulated via direct or indirect means, phosphorylates its accepted target PKA but also
phosphorylates the preferred PKG target VASPSer239. Similarly, cyclic GMP, also activated
directly or indirectly, phosphorylates its accepted target VASPSer239 as well as the supposed
PKA substrate VASPSer157. We have also documented abilities of both cyclic AMP and cyclic
GMP to stimulate members of the diverse PKC family [30]. Recently we observed that AMP
kinase, another Ser/Thr enzyme, not only phosphorylates its canonical target VASPThr278 [32]
but also has capacity to phosphorylate the preferred PKA target VASPSer157, yet interestingly
without observable effects on VASPSer239 [33,34]. Recently it was reported that PKD, a down‐
stream product of PKC and a Ser/Thr kinase involved in ECM receptor-mediated signal
transduction pathways, phosphorylates both its reported VASPSer322 site as well as the PKA
VASPSer157 site [35]. Considering this crosstalk among these kinases and the target VASP, it is
important to note that while Ser/Thr and Tyr kinases can target a specific residue, these
enzymes are also attracted to flanking residues alongside the known phosphoacceptor site. By
this virtue, the catalytic cleft of the kinase interacts not only with its preferred Ser, Thr,
and/or Tyr phosphoacceptor residue but also with their flanking regions, thereby binding to
similar recognition sequences among similar substrate family members and in turn reducing
their specificity for a particular residue. This kinase crosstalk then affords broad impact of
upstream kinase signaling but also clouds precision of downstream targeting. Regardless of
this observed promiscuity, these critical cyclic nucleotide/kinase/VASP signaling cascades
elicit a vast array of significant biological effects in VSM and are of critical importance in
vascular physiology and pathology.
Functionally, VASP operates as an anticapping protein and assists in the down-regulation of
platelet adhesion molecules, promotes endothelial barrier protection, and assists in vessel
structural integrity [36,37]. VASP was recently shown to protect against vascular inflammation
and insulin resistance following exposure to high-fat diet [36]. In cancer research, VASP is
implicated as a possible pharmacotherapeutic target aimed at controlling aberrant cancer cell
migration [35,36]. In those studies, protection by VASP is attributed to its multiple phosphor‐
ylation residues (namely Ser157, Ser239, Thr278, and Ser322) that significantly and differentially
impact its function as an actin-binding protein. Interestingly, like cancer cells, VSM cells rely
on reorganization of their actin cytoskeleton as their primary mechanism of movement [38-40],
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and so VASP serves as a plausible target for control of migration in the context of CVD. In our
lab, we have recently examined site-specific phosphorylated VASP as a controller of VSM
migration and proliferation in commercial and primary VSM cells [19,28-31]. In summary,
results suggest that VASPSer239 acts primarily to control cell migration, yet VASPSer157 serves to
regulate cell proliferation, both key components in CVD pathogenesis. Also, by virtue of its
name, VASP is inherently involved in regulation of hemodynamics via its upstream activators
(cyclic AMP/cyclic GMP/kinases) and downstream effectors. In the context of an endothelial-
compromised (diseased) blood vessel with fenestration of the intimal–medial barrier and
basement membrane, underlying VSM cells become exposed to elevated levels of blood flow
and associated mechanical forces. In this regard, recent guidance from the American Heart
Association [1] states physical activity as the first-line homeopathic therapy at ameliorating
the symptoms associated with PAD, a main form of CVD. While it is known that exercise is
beneficial for the circulatory system via formation of collaterals and arterialization of existing
capillaries, our question of how hemodynamic forces alleviate PAD remains unanswered [41,
42]. Since exercise was recently shown to stimulate phosphorylated VASP [43], VASP is likely
linked to beneficial outcomes observed following exercise. With this in mind, using a 10 day
treadmill exercise regimen, preliminary observations show that hyperemic fluid shear stress
has capacity to increase VASPSer239 in rat aorta segments compared to sedentary controls (Figure
6). This dilatory response can increase circumferential hoop stress and in the presence of an
increased pressure head, consequently increase fluid shear stress. This effect can drastically
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Figure 6. Exercise increases VASPSer239 in rat thoracic aorta (TA) segments following a 10 day treadmill running proto‐
col. A: Tissue homogenates of TA sections were pooled from 4 animals per group (sedentary (Sed.) or exercised (Ex.))
and immunoprecipitation (IP) for VASPSer239 was performed. IP fractions were then subjected to gel electrophoresis fol‐
lowed by ECL Western blotting for VASPSer239. B represents results from densitometry for VASPSer239 from TA homoge‐
nates in Sed. or Ex. cohorts. Preliminary results show that exercise-induced shear stress approximately doubles
VASPSer239 expression in rat TA sections compared to sedentary controls. These early results suggest that shear stress
acts to reduce VSM migration via VASPSer239, which may serve as a mechanism underlying beneficial effects of exercise
against CVD.
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serve to mitigate abnormal cellular migration and growth associated with CVD. Indeed, these
early findings offer support for VASP and phosphorylated VASP species, as crucial cytoske‐
letal and signal transduction proteins, as capable of controlling deleterious vascular growth
integral for CVD.
Indeed, VASP holds great promise regarding its ability to control VSM growth underlying
vascular disorders but represents just one of the many end-targets of cyclic nucleotide-driven
cellular signals. Vascular cyclic AMP and cyclic GMP and their Ser/Thr kinases also have
capacity to exert regulatory control over synthetic TGF-beta signaling [19] as well as other cell-
to-cell and focal adhesion/cytoskeletal proteins including gap junctional connexins [46,47],
paxillin [34,48], G-actin and F-actin rations [34], and FAK [28,34]. We have also reported on
capacities of these signals to regulate ECM-degrading MMPs as a potential route of action in
VSM [34,49]. The broad influence of cyclic nucleotide signaling and its many end-target
proteins including VASP and associated cytoskeletal components in VSM presents an attrac‐
tive and biologically feasible therapeutic strategy aimed against basic elements of CVD and
many forms of vascular dysfunction.
10. Summary and conclusions
The paramount importance of CVD on morbidity and mortality in the United States and
globally is clear, yet inefficiencies in the clinical translation of basic science findings show that
the underlying mechanisms of CVD are still not completely known and fully effective therapies
against CVD are still needed. Indeed, despite ample basic and clinical research, CVD preva‐
lence is estimated to increase 10% and the economic burden of CVD is projected to triple within
the next 20 years with latest estimates that >40% of the adult US population will have some
form of CVD by the year 2030 [50]. In our incessant search for possible targets to help control
and possibly eliminate CVD, the pivotal influence of VSM growth in playing key roles in CVD
pathogenesis is clear. We and others have focused our efforts on identifying and characterizing
unique elements behind VSM biology and signaling under healthy as well as pathologic
conditions, and findings to date reveal significant insights into many biochemical, molecular,
and cellular elements foundational to CVD with perhaps that of cyclic nucleotide signaling at
the forefront. Given its ubiquitous nature and multifaceted diverse functions, cyclic AMP and
cyclic GMP and their downstream kinases and targets including VASP represent key elements
capable of controlling deleterious vascular growth that serves as a basis for CVD. Only through
persistent basic science and clinical investigation do we hope to fully understand these crucial
factors that hold great promise in our seemingly never-ending struggle to combat and control
CVD.
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